Doubling the dose of Clopidogrel restores the loss of antiplatelet effect induced by esomeprazole

Thrombosis Research

Volumn 128, Issue 5, 2011, Pages 458-462

  Moceri, Pamela ^a   Doyen, Denis ^a   Cerboni, Pierre ^a   Ferrari, Emile ^a  

^a PASTEUR HOSPITAL   (France)

Author keywords

Antiplatelet therapy; Clopidogrel resistance; Coronary artery disease; Drug drug interaction

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; ESOMEPRAZOLE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PURINERGIC P2Y12 RECEPTOR; RANITIDINE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CROSSOVER PROCEDURE; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; PLATELET REACTIVITY; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

AGED; ANTI-ULCER AGENTS; ASPIRIN; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RANITIDINE; TICLOPIDINE;

EID: 80055079963     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.06.029     Document Type: Article

References (49)

1. S. Matetzky, B. Shenkman, V. Guetta, M. Shechter, R. Bienart, and I. Goldenberg Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation 109 2004 3171 3175
2. P. Barragan, J.L. Bouvier, P.O. Roquebert, G. Macaluso, P. Commeau, and B. Comet Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilatator-stimulated phosphoprotein phosphorylation Catheter Cardiovasc Interv 59 2003 295 302 (Pubitemid 36792384)
3. V.L. Serebruany, S.R. Steinhubl, P.B. Berger, A.I. Malinin, D.L. Bhatt, and E.J. Topol Variability in platelet responsiveness to clopidogrel among 544 individuals J Am Coll Cardiol 45 2005 246 251 (Pubitemid 40094733)
4. M. Kazui, Y. Nishiya, T. Ishizuka, K. Hagihara, N.A. Farid, and O. Okazaki Identification of the human cytochrome p450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite Drug Metab Dispos 38 2010 92 99
5. H.J. Bouman, E. Schömig, J.W. van Werkum, J. Velder, C.M. Hackeng, and C. Hirschhäuser Paraoxonase-1 is a major determinant of clopidogrel efficacy Nat Med 17 2011 110 116
6. J.P. Collet, J.S. Hulot, A. Pena, E. Villard, J.B. Esteve, and J. Silvain Cytochrome P450 2 C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study Lancet 373 2009 309 317
7. T. Simon, C. Verstuyft, M. Mary-Krause, L. Quteineh, E. Drouet, and N. Méneveau Genetic determinants of response to clopidogrel and cardiovascular events N Engl J Med 360 2009 363 375
8. J.L. Mega, S.L. Close, S.D. Wiviott, L. Shen, R.D. Hockett, and J.T. Brandt Cytochrome P-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
9. T. Yin, and T. Miyata Pharmacogenomics of clopidogrel: Evidence and perspectives Thromb Res 2011 10.1016/ j.thromres.2011.04.010
10. D. Sibbing, W. Koch, S. Massberg, R.A. Byrne, J. Mehilli, and S. Schulz No association of paraoxonase-1 Q192R genotypes with platelet response to clopidogrel and risk of stent thrombosis after coronary stenting Eur Heart J 2011 10.1093/eurheartj/ehr155
11. E.R. Bates, W.C. Lau, and D.J. Angiolillo clopidogrel-drug interactions J Am Coll Cardiol 57 2011 1251 1263
12. M. Gilard, B. Arnaud, J.C. Cornily, G. Le Gal, K. Lacut, and G. Le Calvez Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
13. C.S. Zuern, T. Geisler, N. Lutilsky, S. Winter, M. Schwab, and M. Gawaz Effect of comedication with proton pump inhibitors on post-interventional residual platelet aggregation in patients undergoing coronary stenting treated by dual antiplatelet therapy Thromb Res 125 2010 e51 e54
14. D.J. Angiolillo, C.M. Gibson, S. Cheng, C. Ollier, O. Nicolas, and L. Bergougnan Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies Clin Pharmacol Ther 89 2011 65 74
15. T. Andersson, C. Cederberg, G. Edvardsson, A. Heggelund, and P. Lundborg Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole Clin Pharmacol Ther 47 1990 79 85 (Pubitemid 20041214)
16. T. Andersson, M. Hassan-Alin, G. Hasselgren, and K. Röhss Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole Clin Pharmacokinet 40 2001 523 537 (Pubitemid 32743165)
17. N. Yeomans, A. Lanas, J. Labenz, S.V. van Zanten, C. van Rensburg, and I. Rácz Efficacy of esomeprazole (20 mg Once Daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin Am J Gastroenterol 103 2008 1 9
18. D.L. Bhatt, J. Scheiman, N.S. Abraham, E.M. Antman, F.K. Chan, and C.D. Furberg American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents J Am Coll Cardiol 52 2008 1502 1517
19. A.M. Dyszkiewicz-Korpanty, A. Kim, J.D. Burner, E.P. Frenkel, and R. Sarode Comparison of a rapid platelet function assay - Verify NowTM Aspirin - with whole blood impedance aggregometry for the detection of aspirin resistance Thromb Res 120 2007 485 488 (Pubitemid 47094907)
20. P.A. Gurbel, K.P. Bliden, W. Samara, J.A. Yoho, K. Hayes, and M.Z. Fissha Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study J Am Coll Cardiol 46 2005 1827 1832 (Pubitemid 41579803)
21. A.R. Hobson, G. Petley, G. Morton, K.D. Dawkins, and N.P. Curzen Point-of-care platelet function assays demonstrate reduced responsiveness to clopidogrel, but not aspirin, in patients with Drug-Eluting Stent Thrombosis whilst on dual antiplatelet therapy Thromb J 6 2008 1 6
22. M.J. Price, S. Endemann, R.R. Gollapudi, R. Valencia, C.T. Stinis, and J.P. Levisay Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation Eur Heart J 29 2008 992 1000 (Pubitemid 351844676)
23. J.L. Orford, R. Lennon, S. Melby, P. Fasseas, M.R. Bell, and C.S. Rihal Frequency and correlates of coronary stent thrombosis in the modern era: analysis of a single center registry J Am Coll Cardiol 40 2002 1567 1572 (Pubitemid 35253633)
24. J.M. Siller-Matula, G. Christ, I.M. Lang, G. Delle-Karth, K. Huber, and B. Jilma Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phosphorylation assay J Thromb Haemost 8 2010 351 359
25. D. Sibbing, T. Morath, S. Braun, J. Stegherr, J. Mehilli, and W. Vogt Clopidogrel response status assessed with Multiplate point-of-care analysis and the incidence and timing of stent thrombosis over six months following coronary stenting Thromb Haemost 103 2010 151 159
26. T. Cuisset, C. Frere, J. Quilici, R. Poyet, B. Gaborit, and L. Bali Comparison of omeprazole and pantoprazole influence on a high 150 mg clopidogrel maintenance dose: The PACA (Proton pump inhibitors And Clopidogrel Association) prospective randomized study J Am Coll Cardiol 54 2009 1149 1153
27. J.M. Siller-Matula, A.O. Spiel, I.M. Lang, G. Kreiner, G. Christ, and B. Jilma Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel Am Heart J 157 148 2009 e1 e5
28. E. Pezalla, D. Day, and I. Pulliadath Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors J Am Coll Cardiol 52 2008 1038 1039
29. (abstr) R.E. Aubert, R.S. Epstein, J.R. Teagarden, F. Xia, J. Yao, and Z. Desta Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study Circulation 118 2008 S815
30. D.N. Juurlink, T. Gomes, D.T. Ko, P.E. Szmitko, P.C. Austin, and J.V. Tu A population-based study of the drug interaction between proton pump inhibitors and clopidogrel CMAJ 180 2009 713 718
31. J.A. Rassen, N.K. Choudhry, J. Avorn, and S. Schneeweiss Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome Circulation 120 2009 2322 2329
32. K.M. Stockl, L. Le, A. Zakharyan, A.S. Harada, B.K. Solow, and J.E. Addiego Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor Arch Intern Med 170 2010 704 710
33. J.M. Siller-Matula, B. Jilma, K. Schrör, G. Christ, and K. Huber Effect of proton pump inhibitors on clinical outcome in patients treated with clopidogrel: a systematic review and meta-analysis J Thromb Haemost 8 2010 2624 2641
34. M. O'Donoghue, E. Braunwald, E.M. Antmann, S.A. Murphy, E.R. Bates, and Y. Rozenman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomized trials Lancet 374 2009 989 997
35. D.L. Bhatt, B.L. Cryer, C.F. Contant, M. Cohen, A. Lanas, and T.J. Schnitzer Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 363 2010 1909 1917
36. R. Paniccia, E. Antonucci, A.M. Gori, R. Marcucci, C. Giglioli, and D. Antoniucci Different methodologies for evaluating the effect of clopidogrel on platelet function in high-risk coronary artery disease patients J Thromb Haemost 5 2007 1839 1847 (Pubitemid 47288940)
37. R. Paniccia, E. Antonucci, A.M. Gori, R. Marcucci, S. Poli, and E. Romano Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment Am J Clin Pathol 128 2007 143 149 (Pubitemid 47121727)
38. N.J. Breet, J.W. van Werkum, H.J. Bouman, J.C. Kelder, H.J. Ruven, and E.T. Bal Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation JAMA 303 2010 754 762
39. J.L. Ferreiro, M. Ueno, S.D. Tomasello, D. Capodanno, B. Desai, and K. Dharmashankar Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover study Circ Cardiovasc Interv 4 2011 273 279
40. D.S. Small, N.A. Farid, C.D. Payne, G.J. Weerakkody, Y.G. Li, and J.T. Brandt Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel J Clin Pharmacol 48 2008 475 484 (Pubitemid 351389118)
41. K. Barada, W. Karrowni, M. Abdallah, W. Shamseddeen, A.I. Sharara, and H.A. Dakik Upper gastrointestinal bleeding in patients with acute coronary syndromes: clinical predictors and prophylactic role of proton pump inhibitors J Clin Gastroenterol 42 2008 368 372 (Pubitemid 351450621)
42. G.C. Schreiner, L. Laine, S.A. Murphy, C.P. Cannon TIMI study group Evaluation of proton pump inhibitor use in patients with acute coronary syndromes based on risk factors for gastrointestinal bleed Crit Pathw Cardiol 6 2007 169 172 (Pubitemid 350307803)
43. S.D. Wiviott, E. Braunwald, C.H. McCabe, G. Montalescot, W. Ruzyllo, and S. Gottlieb Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes N Engl J Med 357 2007 2001 2015 (Pubitemid 350106708)
44. S. Husted, H. Emanuelsson, S. Heptinstall, P.M. Sandset, M. Wickens, and G. Peters Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
45. L. Wallentin, R.C. Becker, A. Budaj, C.P. Cannon, H. Emanuelsson, and C. Held Ticagrelor versus clopidogrel in patients with acute coronary syndromes N Engl J Med 361 2009 1045 1057
46. S.C. Smith Jr., T.E. Feldman, J.W. Hirshfeld Jr., A.K. Jacobs, M.J. Kern, and S.B. King III American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 47 2006 216 235 (Pubitemid 43005194)
47. G. Lemesle, C. Delhaye, A. Sudre, D. Broucqsault, G. Rosey, and C. Bauters Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome Am Heart J 157 2009 375 382
48. S.R. Mehta, J.F. Tanguay, J.W. Eikelboom, S.S. Jolly, C.D. Joyner, and C.B. Granger Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial Lancet 376 2010 1233 1243
49. A.T. Cole, S. Brundell, N. Hudson, A.B. Hawthorne, Y.R. Mahida, and C.J. Hawkey Ranitidine: differential effects on gastric bleeding and mucosal damage induced by aspirin Aliment Pharmacol Ther 6 1992 707 715 (Pubitemid 23004319)